# Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors

> **NCT05559541** · PHASE1,PHASE2 · TERMINATED · sponsor: **Akeso** · enrollment: 33 (actual)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** AK119
- **DRUG:** AK104

## Key facts

- **NCT ID:** NCT05559541
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-12-15
- **Primary completion:** 2024-05-31
- **Final completion:** 2024-05-31
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** Development strategy adjustment
- **Last updated:** 2025-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05559541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05559541, "Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05559541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*